DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Alesse (Levonorgestrel / Ethinyl Estradiol) - Published Studies

 
 



Alesse Related Published Studies

Well-designed clinical trials related to Alesse (Levonorgestrel / Ethinyl Estradiol)

Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. [2011.03]

Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. [2009.12]

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. [2005.02]

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. [2005.02]

A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. [2005.01]

Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. [2004.02]

The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. [2003.05]

Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women. [2002.12]

The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol. [2002.09]

Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. [2002.09]

Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. [2002.04]

An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. [2002.03]

Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. [2002.01]

Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers. [2001.12]

The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. [2001.11]

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. [2001.09]

Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. [2001.07]

Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. [2001.07]

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. [2000.07]

Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. [2000.07]

A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. [1999.11]

A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study. [1999.06]

Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. [1999.06]

Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. [1999.05]

Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms). [1999.03]

Levonorgestrel versus the "Yuzpe" regimen. New choices in emergency contraception. [1999.03]

Short-term treatment with levonorgestrel does not antagonize the ethinyl estradiol-induced increase of uterine blood flow in postmenopausal women. [1997.09]

Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. [1994.03]

Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids. [1993.10]

A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. [1993.03]

A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study. [1993.01]

Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. [1992.11]

A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. [1992.06]

Interrelationship of serum levonorgestrel and sex hormone-binding globulin levels following vaginal and oral administration of combined steroid contraceptive tablets. [1992.02]

Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. [1992.02]

A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. [1992]

A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. [1991.01]

A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism. [1990.11]

Two-year carbohydrate metabolism studies in women using a norethindrone or levonorgestrel triphasic oral contraceptive. [1990.09]

Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. [1990.01]

Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. [1987.10]

The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form. [1987.09]

ICMR Task Force Study on hormonal contraception. Transfer of norethisterone (NET) and levonorgestrel (LNG) from a single tablet into the infant's circulation through the mother's milk. [1987.06]

Clinical and metabolic effects of gestodene and levonorgestrel. [1987]

The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. [1986.10]

Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. [1985.04]

Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version. [1983.05]

Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. [1979.07]

Well-designed clinical trials possibly related to Alesse (Levonorgestrel / Ethinyl Estradiol)

A trial of contraceptive methods in women with systemic lupus erythematosus. [2005.12.15]

Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. [2005.07]

Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. [2005.07]

Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. [2005.05]

Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]

Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception. [2004.11]

Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. [2004.11]

A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. [2004.09]

Effect of four oral contraceptives on hemostatic parameters. [2004.08]

Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]

Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. [2004.06]

Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. [2004.04]

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. [2004.02.01]

Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. [2004.02]

Effect of hormonal emergency contraception on bleeding patterns. [2004.02]

An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. [2004.01]

Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. [2003.10]

A multicenter, randomized study of an extended cycle oral contraceptive. [2003.08]

Advance supply of emergency contraception. effect on use and usual contraception--a randomized trial. [2003.07]

Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. [2003.06]

A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. [2003.05]

Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. [2003.05]

Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. [2003.05]

Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. [2003.04]

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. [2003.03]

Vitamin D receptor gene polymorphism and bone metabolism during low-dose oral contraceptive use in young women. [2003.01]

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. [2003.01]

Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. [2003.01]

Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. [2002.12]

Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. [2002.11]

Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. [2002.09]

Emergency contraception. [2002.08.06]

Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. [2002.07]

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. [2002.07]

L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. [2002.06]

Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study. [2002.05]

A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. [2002.05]

Long-term effects of combined oral contraceptives on markers of endothelial function and lipids in healthy premenopausal women. [2002.03]

Effect of dienogest-containing oral contraceptives on lipid metabolism. [2002.03]

Effects of the Yuzpe regimen, given during the follicular phase, on ovarian function. [2002.02]

Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. [2002.02]

Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. [2001.11]

Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. [2001.11]

Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. [2001.06]

Biphasic versus triphasic oral contraceptives for contraception. [2001]

Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). [2001]

Clinical management of functional ovarian cysts: a prospective and randomized study. [2000.12]

Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH). [2000.11]

Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. [2000.07]

Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive. [2000.03]

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. [1999.12.11]

Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. [1999.12]

Effect of low-dose oral contraceptives on androgenic markers and acne. [1999.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017